LNCaP Xenograft Model Service for Prostate Cancer

The LNCaP cell line provides a highly characterized in vivo platform for investigating androgen-dependent prostate cancer and the molecular mechanisms of hormone-sensitive tumor growth. As a premier pre-clinical contract research organization, Alfa Cytology delivers an integrated, high-precision LNCaP Xenograft Model Service, meticulously optimized to provide reproducible, audit-ready data packages that accelerate your prostate cancer drug discovery and development pipeline.

Overview of LNCaP Xenograft Model for Prostate Cancer

The LNCaP xenograft model is an essential in vivo translational system widely utilized in oncology research for studying prostate adenocarcinoma. By transplanting human LNCaP cells into immunodeficient rodent hosts, this model effectively reproduces the androgen-responsive growth characteristics, histopathological architecture, and PSA-secreting patterns typical of human hormone-sensitive prostate malignancies.

Biologically, the LNCaP model is highly valued for its expression of functional androgen receptors (AR) and its sensitivity to androgen-deprivation therapies (ADT). This unique molecular profile makes it a gold-standard system for evaluating the efficacy of next-generation AR inhibitors, hormone-based interventions, and novel therapies targeting the androgen-signaling axis. The model maintains critical phenotypic features of human prostate cancer, demonstrating reliable tumor formation and predictable responsiveness to pharmacological agents in an in vivo environment. Consequently, the LNCaP model is extensively deployed in pre-clinical screening programs to assess the anti-tumor potency of novel therapeutic candidates.

Fig 1. Morphological analysis of LNCaP cells treated with J. spicigera extract at 250 and 500 µg/mL for 24 h, 48 h and 72 h. (Bravo-Espinoza I, et al., 2026)

Cell Line Information: LNCaP

The LNCaP cell line is derived from a metastatic site (left supraclavicular lymph node) of human prostate carcinoma. These cells exhibit stable growth characteristics in vitro and retain key characteristics of androgen-sensitive prostate cancer, making them a foundational choice for pre-clinical model development.

Our Services

Workflow of LNCaP Xenograft Model Construction

• Cell Culture & Quality Control: Human LNCaP cells are expanded in vitro using certified nutrient media under optimized physiological conditions. STR authentication and mycoplasma screening are performed prior to inoculation to ensure absolute genetic integrity and purity.
• Host Selection & Preparation: Immunodeficient rodent models are utilized for tumor engraftment, with all animals maintained in a controlled, pathogen-free environment to ensure physiological stability and consistency throughout the study.
• Precision Inoculation: A calibrated suspension of high-viability LNCaP cells is prepared, often supplemented with an extracellular matrix (e.g., Matrigel) to optimize take efficiency. Cells are inoculated in vivo via subcutaneous injection into the host flank to facilitate the development of a measurable, solid tumor.
• Longitudinal Monitoring: Tumor size is measured systematically using digital calipers to monitor volume progression. Animal health, activity, and body weight are recorded periodically to document systemic tolerance and clinical status.
• Randomization & Treatment: Once solid tumors reach a predefined, statistically significant volume, animals are randomized into matched cohorts to ensure baseline parity before the initiation of customized therapeutic dosing regimens.

Fig 2. LNCaP Xenograft Model Construction Workflow

Case Study - LNCaP Xenograft Model Development

A pre-clinical validation study was conducted using the LNCaP xenograft model to evaluate the therapeutic efficacy of a novel androgen receptor antagonist. Following the successful subcutaneous inoculation of LNCaP cells into immunodeficient mice, the host animals developed firm, measurable solid tumors. The treatment group demonstrated a clear, statistically significant inhibition of tumor growth compared to the vehicle-treated control group, confirming the model's sensitivity and reliability for screening novel therapeutic interventions in a hormone-sensitive setting.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Profound experience in managing specialized prostate cancer lineages, providing highly reproducible in vivo translational platforms for complex hormonal-resistance research.
• Rigorous Quality Control: Meticulous cell validation and standardized operating procedures that minimize experimental variability across all project stages.
• Tailored Experimental Design: Highly flexible protocols that adapt to specific animal strain requirements, custom dosing schedules, and unique compound properties.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready report providing comprehensive tumor growth metrics and statistical validations.

Contact us

Accelerating your prostate cancer drug pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our LNCaP platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.